In this review:
ARP + ATR inhibitors in acquired PARPi-resistant recurrent ovarian cancer
PFS and PFS2 by disease stage in patients with HRD-positive newly diagnosed advanced ovarian cancer receiving bev with olaparib/placebo maintenance
Potential biomarkers identified from MILO/ ENGOT-ov11 study of binimetinib vs chemotherapy in recurrent LGSOC
DCVAC + chemotherapy in newly diagnosed EOC after primary PDS: Biomarker exploratory analysis
Pembrolizumab + bev + PLD in platinum-resistant EOC
Underutilisation of germline BRCA testing in ovarian cancer
Serum-based assay for adnexal mass risk of ovarian malignancy
Disparities in ovarian cancer treatment and OS according to race
Does aggressive surgery only benefit patients with less advanced ovarian cancer?
Please login below to download this issue (PDF)